TOFIDENCE is Bio-Thera’s first productapproved by USFDA. TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United States TOFIDENCE is the first biosimilar toActemra approved by USFDA GUANGZHOU, C...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI ® (格乐立 ® ), a biosimilar to Humira ® (adalimumab), is now available in China. QLETLI ® (格乐立 ® ), the first adalimumab biosimilar approved by the Chi...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a Phase I clinical study to compare the phar...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved QLETLI ® (格乐立 ® ) for all eligible indications of the reference product, Humira ® (adalimumab)...
